In Utero Exposure to Selective Serotonin Reuptake Inhibitors and Risk for Autism Spectrum Disorder
In Utero Exposure to Selective Serotonin Reuptake Inhibitors and Risk for Autism Spectrum Disorder
复制标题
DOI：
10.1007/s10803-014-2128-4
复制
发表时间：
2014-10-01
影响因子：
3.9
通讯作者：
Newschaffer, Craig J.
中科院分区：
文献类型：
--
作者：
Gidaya, Nicole B.;Lee, Brian K.;Newschaffer, Craig J.
我们调查了在怀孕期间使用选择性血清素再摄取抑制剂（SSRIs）是否与自闭症谱系障碍（ASD）风险增加有关。这项研究使用丹麦的健康和人口登记来获取有关处方药、自闭症谱系障碍诊断、健康和社会经济状况的信息。在怀孕期间，有1.5%的病例和0.7%的对照组暴露于SSRIs，并且随着使用时间的延长，观察到更高的效果估计。我们发现有证据表明，在子宫内接触SSRIs会增加儿童患ASD的风险。这些结果，虽然增加了关于产前药物暴露作为潜在ASD风险因素的有限知识，但需要与孕妇使用指示性药物的益处相平衡。
We investigated whether there is an association between increased risk for autism spectrum disorders (ASD) and selective serotonin reuptake inhibitors (SSRIs) used during pregnancy. This study used Denmark's health and population registers to obtain information regarding prescription drugs, ASD diagnosis, and health and socioeconomic status. There were 1.5 % of cases and 0.7 % of controls exposed to SSRIs during the pregnancy period, and higher effect estimates observed with longer use. We found evidence that in utero exposure to SSRIs increases a child's risk associated with ASD. These results, while adding to the limited knowledge on prenatal pharmacological exposures as potential ASD risk factors, need to be balanced against the benefits of indicated medication use by pregnant mothers.